Abstract
We report a case of a patient with squamous cell carcinoma (SCC) who developed myasthenia gravis (MG), myositis, and myocarditis after receiving cemiplimab, an anti-PD-1 immune checkpoint inhibitor (ICI). Case Presentation. An 86-year-old man with metastatic periocular SCC presented with decreased vision in the left eye, severe fatigue, and lower back and bilateral hip pain 3 weeks after receiving cemiplimab. Within hours, he developed dysphonia, pharyngeal secretions, and dysphagia, necessitating intubation. Endomyocardial biopsy revealed active lymphocyte-mediated necrosis consistent with ICI-induced myocarditis. Anti-striated muscle and anti-acetylcholine receptor antibodies were elevated, consistent with myositis and myasthenia gravis. Despite plasma exchange therapy, steroids, and intravenous immunoglobulin, he died from cardiac arrest. The presence of myasthenia gravis, myocarditis, or myositis should prompt evaluation for all three toxicities as they may represent an overlap syndrome. The severity of these immunotoxicities highlights the need for clinicians to suspect multiple simultaneous adverse effects of ICIs.
References
Oct 23, 2012·International Immunology·Marie-Laure ThibultDaniel Olive
Nov 13, 2015·American Journal of Clinical Oncology·Elizabeth I Buchbinder, Anupam Desai
Jun 23, 2016·Journal for Immunotherapy of Cancer·Mehmet Asim BilenPadmanee Sharma
Jul 16, 2016·Cancer Science·Toshihiro KimuraHironobu Ihn
Oct 26, 2016·Journal for Immunotherapy of Cancer·Bridgette A KanzDouglas B Johnson
Dec 21, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C L HaddoxM P Goetz
Feb 28, 2017·Journal for Immunotherapy of Cancer·Eileen ShiuanDouglas Johnson
Feb 28, 2017·Cancer·Douglas B JohnsonAlexander M Menzies
Aug 20, 2017·Neurology·Shigeaki SuzukiMakoto Matsui
Dec 5, 2017·Journal of Immunotherapy·Teerin LiewluckMichelle L Mauermann
Mar 15, 2018·Lancet·Javid J MoslehiDouglas B Johnson
Jun 5, 2018·The New England Journal of Medicine·Michael R MigdenMatthew G Fury
Aug 6, 2018·Current Neurology and Neuroscience Reports·Justin C KaoTeerin Liewluck
Aug 10, 2018·Neurology·Mehdi TouatSarah Léonard-Louis
Nov 21, 2018·Drugs·Anthony Markham, Sean Duggan
Nov 28, 2018·Annals of Clinical and Translational Neurology·Koutaro TakamatsuYukio Ando
Mar 14, 2019·Journal of Autoimmunity·Morinobu SekiShigeaki Suzuki
May 24, 2019·Journal for Immunotherapy of Cancer·Douglas B JohnsonJoe-Elie Salem
Jun 12, 2019·Case Reports in Immunology·Mahdieh Fazel, Patrick M Jedlowski
Oct 28, 2019·Journal of Clinical Medicine·Nora MöhnThomas Skripu
Nov 16, 2019·Journal for Immunotherapy of Cancer·Satya Das, Douglas B Johnson
Citations
Jan 3, 2021·Orbit·Edward J Wladis, Madhavi L Kambam
Nov 14, 2020·Arthritis & Rheumatology·Laura C Cappelli, Clifton O Bingham
Apr 1, 2021·Drugs·Blake H FortesLauren A Dalvin
Apr 18, 2021·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Renato OliveiraMiguel Oliveira Santos
Jun 10, 2021·Brain and Behavior·Wei ChengPing Chen
Jul 7, 2021·Korean Circulation Journal·Abdulrazzak ZarifaPeter Y Kim
Aug 12, 2021·The Oncologist·Ranjan PathakRavi Salgia
Aug 24, 2021·Tumori·Fabio CaninoMassimo Dominici
Aug 27, 2021·Frontiers in Cardiovascular Medicine·Rishi RikhiRohit Moudgil
Oct 14, 2021·Expert Opinion on Drug Safety·Alessia VillaniMassimiliano Scalvenzi